The trial also revealed statistically significant and clinically meaningful gains in key patient-reported outcomes
Iktos will deploy its AI-driven tools to accelerate the identification of optimized small-molecule candidates against a currently undisclosed oncology target
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs
Dr. Reddy’s Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is an antihistamine eye drop, indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
Vanda strongly disputes the FDA’s reasoning
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
Subscribe To Our Newsletter & Stay Updated
